Ra Pharmaceuticals (RARX) PT Set at $21.00 by BMO Capital Markets

Ra Pharmaceuticals (NASDAQ:RARX) received a $21.00 price target from investment analysts at BMO Capital Markets in a research report issued on Thursday. The brokerage currently has a “buy” rating on the stock. BMO Capital Markets’ target price would suggest a potential upside of 75.44% from the stock’s current price.

Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 5th. ValuEngine raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, August 14th. Credit Suisse Group set a $25.00 target price on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday, October 19th. Finally, Raymond James raised shares of Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a report on Wednesday, October 10th. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $20.80.

Shares of Ra Pharmaceuticals stock opened at $11.97 on Thursday. Ra Pharmaceuticals has a 1 year low of $4.78 and a 1 year high of $19.43. The firm has a market cap of $446.29 million, a price-to-earnings ratio of -4.97 and a beta of 2.08.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Wednesday, November 7th. The company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.02). As a group, equities analysts anticipate that Ra Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Ra Pharmaceuticals by 33.3% during the third quarter. BlackRock Inc. now owns 2,049,933 shares of the company’s stock worth $37,084,000 after buying an additional 512,602 shares in the last quarter. First Manhattan Co. boosted its holdings in Ra Pharmaceuticals by 38.1% during the third quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock worth $19,426,000 after buying an additional 296,419 shares in the last quarter. Millennium Management LLC boosted its holdings in Ra Pharmaceuticals by 50.9% during the first quarter. Millennium Management LLC now owns 671,262 shares of the company’s stock worth $3,564,000 after buying an additional 226,565 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its holdings in Ra Pharmaceuticals by 190.0% during the third quarter. Candriam Luxembourg S.C.A. now owns 435,000 shares of the company’s stock worth $7,869,000 after buying an additional 285,000 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Ra Pharmaceuticals by 5.7% during the second quarter. Citadel Advisors LLC now owns 349,201 shares of the company’s stock worth $3,475,000 after buying an additional 18,754 shares in the last quarter. 73.36% of the stock is currently owned by hedge funds and other institutional investors.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: How to calculate compound interest

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply